Charles Schwab’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-136,167
Closed -$630K 3307
2019
Q1
$630K Sell
136,167
-9,160
-6% -$43.4K ﹤0.01% 2679
2018
Q4
$509K Sell
145,327
-6,429
-4% -$44.7K ﹤0.01% 2766
2018
Q3
$1.53M Buy
151,756
+25,421
+20% +$203K ﹤0.01% 2507
2018
Q2
$915K Buy
126,335
+31,840
+34% +$222K ﹤0.01% 2607
2018
Q1
$571K Buy
94,495
+2,925
+3% +$24.2K ﹤0.01% 2695
2017
Q4
$881K Sell
91,570
-13,242
-13% -$86.7K ﹤0.01% 2547
2017
Q3
$931K Buy
104,812
+24,869
+31% +$257K ﹤0.01% 2526
2017
Q2
$1.01M Buy
79,943
+475
+0.6% +$5.62K ﹤0.01% 2453
2017
Q1
$836K Buy
79,468
+4,275
+6% +$45.5K ﹤0.01% 2479
2016
Q4
$692K Buy
75,193
+3,850
+5% +$43.5K ﹤0.01% 2549
2016
Q3
$842K Sell
71,343
-4,776
-6% -$72.6K ﹤0.01% 2449
2016
Q2
$985K Sell
76,119
-98,129
-56% -$1.43M ﹤0.01% 2352
2016
Q1
$2.79M Buy
174,248
+1,578
+0.9% +$30K ﹤0.01% 1879
2015
Q4
$4.94M Buy
172,670
+96,900
+128% +$2.68M 0.01% 1526
2015
Q3
$2.16M Buy
75,770
+15,381
+25% +$566K ﹤0.01% 2026
2015
Q2
$2.17M Buy
60,389
+6,011
+11% +$187K ﹤0.01% 2037
2015
Q1
$1.58M Buy
54,378
+7,614
+16% +$201K ﹤0.01% 2179
2014
Q4
$986K Buy
46,764
+1,220
+3% +$24.1K ﹤0.01% 2355
2014
Q3
$884K Buy
45,544
+16,144
+55% +$254K ﹤0.01% 2360
2014
Q2
$460K Sell
29,400
-34,830
-54% -$563K ﹤0.01% 2661
2014
Q1
$1.33M Buy
64,230
+42,630
+197% +$845K ﹤0.01% 2148
2013
Q4
$279K Hold
21,600
﹤0.01% 2838
2013
Q3
$263K Buy
+21,600
New +$177K ﹤0.01% 2812

Other funds holding INSY

Charles Schwab's INSY Position: Q2 2019 in Review

Charles Schwab sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 136,167 shares — an estimated $630K sold.

Charles Schwab first reported a position in INSY in Q3 2013 and held it in 23 quarters. The position peaked at $4.94M in Q4 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Charles Schwab reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Charles Schwab sold 136,167 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $630K.
  • Charles Schwab first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 23 quarters.
  • Charles Schwab's Insys Therapeutics, Inc. position peaked at $4.94M in Q4 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Charles Schwab's 13F filing for Q2 2019, filed 9 Aug 2019.